Leber Congenital Amaurosis

Leber congenital amaurosis (LCA) is the most common genetic cause of severe visual impairment in infancy, presenting with profound vision loss from birth or the first months of life.

Its genetic heterogeneity — more than two dozen genes have now been implicated — is directly relevant to families given that one specific subtype, caused by RPE65 mutations, is now treatable with a disease-modifying gene therapy, making accurate molecular diagnosis far more than an academic exercise in this particular condition.

Clinical Presentation

Severe visual impairment or apparent blindness noted by parents within the first few months of life, often the presenting concern that brings the family to medical attention
Nystagmus, typically developing within the first several months as the visual system responds to the profound lack of normal visual input during this critical developmental window
The oculodigital sign — a child persistently pressing, poking, or rubbing their eyes with a finger or knuckle, thought to be a self-generated visual stimulation behavior, and a classic, highly suggestive finding in infants with LCA
Sluggish or paradoxical pupillary responses in some cases
Photophobia or, alternatively, photophilia (an unusual attraction to bright light sources) reported in some affected children, reflecting the underlying photoreceptor dysfunction

Exam Findings

The fundus can appear entirely normal in early infancy, which is genuinely important to know since a normal-appearing retina in a profoundly visually impaired infant does not exclude LCA.

Over time, several fundus changes can develop, including bone-spicule pigmentation resembling retinitis pigmentosa, a salt-and-pepper appearance, macular coloboma-like atrophic lesions, or other patterns depending on the specific underlying genetic cause.

However, the fundus findings alone are rarely sufficient to make the diagnosis, particularly early in the disease course.

Diagnostic Testing

The electroretinogram (ERG) is the single most important diagnostic test, characteristically showing a severely reduced or entirely non-recordable response even when the fundus exam looks unremarkable.

This striking dissociation between a near-normal-appearing fundus and a profoundly abnormal ERG is one of the most diagnostically useful patterns in all of pediatric retinal disease and should prompt ERG testing in any infant with unexplained, severe visual impairment and roving eye movements or nystagmus, regardless of how the fundus looks on direct exam.

Genetics

LCA is genetically heterogeneous, with more than two dozen genes identified across various inheritance patterns (predominantly autosomal recessive, though some genes show other patterns).

The specific gene involved influences not just inheritance and family counseling but, increasingly, treatment eligibility and prognosis, making it the single most important piece of information gathered during the diagnostic process.

RPE65-related LCA is of particular importance given the availability of voretigene neparvovec, a subretinal gene therapy approved for RPE65-mediated inherited retinal disease, making genetic testing to identify this specific subtype an actionable, treatment-relevant step rather than a purely diagnostic or counseling exercise.

Differential Diagnosis

Cortical visual impairment — a normal eye exam, including a normal ERG, distinguishes this cortical cause of poor visual behavior from LCA’s primary retinal dysfunction, discussed in its own dedicated article on this site
Achromatopsia — also presents in infancy with nystagmus and photophobia, but generally with better preserved, though still significantly reduced, overall visual function rather than typical LCA, and a distinct ERG pattern reflecting selective cone rather than combined rod-cone dysfunction, discussed in this site’s coverage of that condition
Congenital stationary night blindness — generally better preserved daytime visual acuity than LCA, with a non-progressive course and its own characteristic ERG pattern, discussed in its own dedicated article on this site
Delayed visual maturation — a distinct, generally more benign condition in which visual behavior is delayed but improves substantially over the first year of life in an otherwise developmentally typical infant, with a normal ERG distinguishing it from LCA
Other early-onset severe retinal dystrophies, sometimes overlapping clinically with LCA and distinguished ultimately through genetic testing

Systemic Associations

While most LCA is an isolated ocular condition, certain genetic subtypes are associated with systemic findings — renal disease (in NPHP-related forms, reflecting overlap with nephronophthisis and related ciliopathies), neurologic and developmental abnormalities, and skeletal findings depending on the specific gene involved — which is another reason molecular diagnosis matters: it can prompt appropriate additional systemic screening in a subset of affected children who might otherwise be assumed to have a purely ocular condition.

Management

Gene-specific therapy is available for RPE65-related LCA, representing a genuine, disease-modifying treatment rather than purely supportive care, and its availability has made prompt, comprehensive genetic testing a standard and urgent part of the workup for any child diagnosed with LCA, since treatment is most effective when started before extensive, irreversible photoreceptor loss has occurred.

For the many other genetic subtypes without a currently available targeted therapy, management remains supportive: low vision services, appropriate educational accommodations, and ongoing monitoring for progressive change or the development of associated systemic findings, with genetic counseling addressing recurrence risk for the family based on the specific inheritance pattern identified.

Given how rapidly the gene therapy field is evolving, families of children with an identified but currently untreatable LCA subtype benefit from periodic reconnection with genetics or retinal specialists, since new targeted treatments continue to enter clinical development and trials.

References

den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Progress in Retinal and Eye Research.
Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec for RPE65-mediated inherited retinal dystrophy. Lancet.
American Academy of Ophthalmology. Basic and Clinical Science Course, Section 12: Retina and Vitreous.

Leber Congenital Amaurosis: A Normal Fundus, a Silent ERG